Skip to main content

Table 3 Results related to the changes in the diary-based symptoms in the study groups

From: A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

Variable

Group

Baseline

Week 8

Mean difference

BSFS

Median,(IQR)

Intervention

5.50 (6–5.07)

4.00 (4.5–3.5)

−1.25(− 0.8-(− 1.9))

Control

5.35 (5.8–5)

5.00 (5.5–4.5)

− 0.30 (0.2-(− 0.6))

P- value

0.34

< 0.001

< 0.001

Bowel frequency per day

Mean ± SD

Intervention

2.30 ± 0.69

1.83 ± 0.43

− 0.48 ± 0.41

Control

2.27 ± 0.63

2.15 ± 0.57

− 0.12 ± 0.31

P- value

0.79

0.01

< 0.001

Abdominal pain score

Mean ± SD

Intervention

1.50 ± 0.45

0.97 ± 0.45

− 0.54 ± 0.41

Control

1.65 ± 0.62

1.44 ± 0.58

− 0.21 ± 0.37

P- value

0.27

< 0.001

0.001

Urgency score

Mean ± SD

Intervention

1.70 ± 0.48

1.13 ± 0.47

− 0.57 ± 0.33

Control

1.57 ± 0.57

1.41 ± 0.53

− 0.16 ± 0.29

P- value

0.31

0.03

< 0.001

Bloating score

Mean ± SD

Intervention

1.61 ± 0.57

1.38 ± 0.39

− 0.25 ± 0.43

Control

1.51 ± 0.57

1.32 ± 0.50

− 0.19 ± 0.35

P- value

0.47

0.69

0.54

Days with urgency

Median,(IQR)

Intervention

5.00 (6–4)

4.00 (5–3)

− 2.00 (0.00- (− 2))

Control

6.00 (6–4)

5.00 (6–3)

0.00 (0.00- (− 2))

P- value

0.36

0.01

0.05

Days with pain

Median,(IQR)

Intervention

5.00 (6–4)

3.00 (4–2)

− 2.00 (− 1-(− 2))

Control

5.00 (5.5–4)

5.00 (5–3.5)

0.00 (0.00- (− 1))

P- value

0.75

< 0.001

< 0.001

Days with diarrhea

Median,(IQR)

Intervention

5.00 (6–4)

4.00 (4–2.75)

− 1.50 (0.75- (− 2.25))

Control

5.00 (6–4)

4.00 (5–4)

0.00 (0.00- (− 2))

P- value

0.84

0.001

0.003

Days with bloating

Median,(IQR)

Intervention

6.00 (7–5)

5.00 (6–3.75)

− 1.00 (0.00- (− 2))

Control

5.00 (7–4.5)

5.00 (6–4)

− 1.00 (1- (− 1.5))

P- value

0.59

0.17

0.11

  1. BSFS Bristol Stool Form scale, IQR Interquartile range, SD Standard deviation